Eli Lilly reported record-breaking Q2 results driven by GLP-1 medications (the class of drugs used for weight loss and diabetes). The company is now positioning artificial intelligence as a key pillar of its long-term strategy.
Summaries like this, in your inbox every morning.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Chunghwa Telecom president Rong-shy Lin said the shift from conversational AI to autonomous AI agents is resha…
CoreWeave fell 5% in premarket trading Friday and was on track to finish the week down 15%, after rebounding f…
Apple and Meta said they would jointly release a new open-weight AI model designed to run on high-end Macs, ai…
Investors put $38.5 billion into Asian startups in Q3, per Crunchbase data
A longtime Anthropic investor told Fortune he expects shares priced around $1.8 trillion, below the company's…
In Q2, billionaires or their funds sold six 'Magnificent Seven' AI stocks
